Mariano Marcos State University

College of Health Sciences

Department of Pharmacy

PHARMACOLOGY 2 (PHBS 107)

MULTIPLE CHOICE: Each of the questions, statements, or incomplete statements can be correctly
answered or completed by one of the suggested answers or phrases. Choose the best answer.
1. Long acting insulin preparations are frequently administered by:
a. Oral route
b. Intramuscular route
c. Intradermal route
d. Subcutaneous route
2. Common side effect of thiazolidinediones is:
a. Dysguesia
b. Hypoglycemia
c. Water retention with weight gain
d. Anemia
3. All of the following are true regarding chlorpropamide except:
a. It is short acting
b. It can cause hypoglycemia in elderly
c. Causes weight gain
d. Associated with alcoholic flush
4. Which of the following drugs does not cause hypoglycemia:
a. Acarbose
b. Insulin
c. Glimepride
d. Nateglinide
5. A patient is receiving insulin and acarbose for diabetes mellitus and developed
hypoglycemia. Which of the following should be used for treatment of hypoglycemia in this
patient?
a. Sucrose
b. Galactose
c. Glucose
d. Starch
6. True about pioglitazone are all except:
a. Metabolized in the liver by CYP3A4
b. Selective agonist for the nuclear peroxisome profilerator activated receptor gamma
c. It causes transcription of gene for carbohydrate and fat metabolism in the absence
of insulin
d. It should be avoided in a patient with cardio-vascular disease
7. All the following statements about alpha-glucosidase inhibitors are true EXCEPT:
a. Reduces intestinal absorption of carbohydrates
b. Effective in both type 1 and 2 diabetes
c. Hypoglycemia is a common and serious side effect
d. Can be used with other oral hypoglycemic agents

Jay Vee S. Racuya, RPh Page 1

 Mariano Marcos State University
College of Health Sciences
Department of Pharmacy

8. All of the following statements about nateglinide are true except?

a. Decreases post-prandial hyperglycemia
b. Hypoglycemia is less common than with sulfonylureas
c. It decreases insulin resistance
d. It acts by releasing insulin\
9. Insulin causes all of the following except:
a. Glycogenesis
b. Glycolysis
c. Lipogenesis
d. Ketogenesis
10. All of the following are true about metformin EXCEPT:
a. Causes little or no hypoglycemia in non diabetic patients
b. Acts by increased insulin secretion
c. Increases peripheral utilization of glucose and decreases absorption of glucose
from intestine
d. When given with alcohol, increases risk of lactic acidosis
11. What will happen if insulin alone is given rapidly in Diabetic Ketoacidosis?
a. Hypokalemia
b. Hypernatremia
c. Hyperkalemia
d. Hypocalcemia
12. All of the following preparations of insulin are rapid and short acting EXCEPT:
a. Lispro
b. Aspart
c. Glargine
d. NPH
13. True about lispro-insulin is:
a. Action is faster and short in duration than regular insulin
b. It is given 30 minutes prior to meal
c. Source is lamb
d. Action is faster and of longer duration than regular insulin
14. Which of the following statements regarding acarbose is FALSE?
a. It acts by inhibiting the enzyme alpha-glucosidase
b. It reduces post-prandial hyperglycemia
c. It decreases the progression of impaired glucose tolerance to overt diabetes
mellitus
d. It can cause hypoglycemia
15. Which of the following drugs is taken during the first part of the meal for the purpose of
delaying absorption of dietary carbohydrates?
a. Acarbose
b. Glipizide
c. Nateglinide
d. Pioglitazone

Jay Vee S. Racuya, RPh Page 2

 Mariano Marcos State University
College of Health Sciences
Department of Pharmacy

16. The most common route of administration of insulin is:

a. Intradermal
b. Subcutaneous
c. Intramuscular
d. Intravenous
17. The correct statement regarding the present status of oral hypoglycemics in diabetes
mellitus is:
a. They are the first choice drug in all cases
b. They should be prescribed only if the patient refuse insulin injections
c. They are used in type 1 diabetes mellitus
d. They are used first in most cases of uncomplicated mild to moderate type 2
diabeties
18. Metformin is NOT effective in lowering of blood sugar level in which of the following
patients?
a. Non diabetics
b. Obese diabetics
c. Type 2 diabetics
d. Diabetics not responding to sulfonylureas
19. Glibenclamide reduces blood glucose in all of the following EXCEPT:
a. Non diabetics
b. Type 1 diabetics
c. Type 2 diabetics
d. Obese diabetics
20. Lactic acidosis is common in:
a. Metformin
b. Sitagliptin
c. Repaglinide
d. Rosiglitazone
21. Adverse effects of insulin include all of the following except:
a. Edema
b. Hyperglycaemia
c. Lipodystrophy
d. Allergy
22. Neutral protamine Hagedorn (NPH) differs from extended insulin Zn suspension in which
of the following actions?
a. It activates receptor tyrosine kinases
b. It causes movement of intracellular glucose transporters to the cell membrane
c. Following subcutaneous injection, it reaches peak plasma concentrations in 6 to
10 h
d. It has a shorter duration of action
e. It increases lipogenesis

Jay Vee S. Racuya, RPh Page 3

 Mariano Marcos State University
College of Health Sciences
Department of Pharmacy

23. The initial and crucial event that enables glyburide to cause the pancreatic b cells to
release insulin is
a. Increased potassium (K) efflux
b. Binding to receptors on the adenosine triphosphate (ATP)–sensitive K+ channels
c. Closing of voltage-dependent Ca channels
d. Decreased phosphorylation reactions
e. Hyperpolarization
24. A 60-year-old diabetic male is treated with pioglitazone. What is the mechanism of action
of pioglitazone?
a. Increased release of endogenous insulin
b. Decreased plasma glucagon levels
c. Increased hepatic gluconeogenesis
d. Increased target tissue sensitivity to insulin
e. Decreased intestinal absorption of glucose
25. A 60-year-old diabetic male on an oral hypoglycemic agent develops abnormal liver
function tests. Which of the following agents can cause this finding?
a. Glyburide
b. Metformin
c. Troglitazone
d. Acarbose
26. Which of the following adverse reactions is not associated with the administration of
chlorpropamide?
a. Water retention
b. Increased tolerance to ethanol
c. Hypoglycemia
d. Hyponatremia
27. A 53-year-old female with NIDDM is started on a sulfonylurea. Which of the following is
one mechanism of action of sulfonylureas?
a. They increase insulin synthesis
b. They release preformed insulin
c. They directly promote glucose uptake by muscle, liver, and adipose tissue
d. They decrease insulin resistance

Jay Vee S. Racuya, RPh Page 4

 Mariano Marcos State University
College of Health Sciences
Department of Pharmacy

For questions 28−34. Match each antidiabetic drug with the appropriate description (each
lettered option can be selected once, more than once, or not at all).

A. Chlorpropamide AC. Miglitol

B. Exenatide AD. NPH insulin
C. Insulin glargine AE. Regular insulin
D. Glyburide BC. Repaglinide
E. Insulin lispro BD. Pioglitazone
AB. Metformin BE. Sitagliptin

28. An insulin preparation with a very fast onset of action.

29. Insulin preparation that can be used for intravenous administration.
30. A dipeptidyl peptidase inhibitor.
31. An inhibitor of an enzyme located on the brush border of the intestinal epithelium.
32. This noninsulin drug regulates transcription of several insulinresponsive genes.
33. A drug used to treat both diabetes mellitus and diabetes insipidus.
34. Insulin preparation with no peak effect.

For questions 35-42. Match each drug on the left with the correct classification on the right.
35. Pramlintide a. sulfonylurea
36. Linagliptin b. biguanide
37. exenatide c. a-glucosidase inhibitor
38. metformin d. meglitinides
39. glipizide e. thiazolidinediones
40. repaglinide ab. amylin analog
41. acarbose ac. dipeptidyl peptidase-4 inhibitor
42. Pioglitazone ad. glucagon-like peptide 1 receptor agonist

For questions 43-52. Match the generic drug name on the left with the correct brand name on
the right.
43. nateglinide a. Byetta
44. metformin b. Symlin
45. insulin glargine c. Januvia
46. rosiglitazone d. Starlix
47. insulin glulisine e. Precose
48. glyburide ab. Lantus
49. exenatide ac. Apidra
50. acarbose ad. Glynase
51. pramlintide ae. Avandia
52. sitagliptin bc. Glucophage

Jay Vee S. Racuya, RPh Page 5